Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1121682

Cover Image

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1121682

Pharmaceutical Contract Sales Outsourcing Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

PUBLISHED:
PAGES: 181 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5795
PDF (Multi-user License)
USD 8795
PDF (Corporate License)
USD 11795

Add to Cart

Description

Table of Contents

List of Tables

The report provides revenue of the pharmaceutical contract sales outsourcing (CSO) market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of pharmaceutical contract sales outsourcing (CSO) market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmaceutical contract sales outsourcing (CSO) market in Europe.

The report delves into the competitive landscape of the pharmaceutical contract sales outsourcing (CSO) market. Key players operating in the pharmaceutical contract sales outsourcing (CSO) market in Europe have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the pharmaceutical contract sales outsourcing (CSO) market profiled in this report.

Show more
Product Code: TMRGL84883

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Market Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Europe Healthcare Industry Overview
  • 5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short /mid / long term impact)

6. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Service, 2017-2031
    • 6.3.1. Personal Promotion
      • 6.3.1.1. Promotional Sales Team
        • 6.3.1.1.1. Dedicated Sales Team
        • 6.3.1.1.2. Syndicated Sales Team
      • 6.3.1.2. Key Account Management
      • 6.3.1.3. Vacancy Management
    • 6.3.2. Non-personal Promotion
      • 6.3.2.1. Tele-detailing
      • 6.3.2.2. Interactive E-detailing
      • 6.3.2.3. Customer Service
      • 6.3.2.4. Medical Science Liaisons
      • 6.3.2.5. Patient Engagement Services
      • 6.3.2.6. Others
    • 6.3.3. Other Services
  • 6.4. Market Attractiveness Analysis, by Service

7. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 7.3.1. Cardiovascular Disorders
    • 7.3.2. Oncology
    • 7.3.3. Metabolic Disorders
    • 7.3.4. Neurology
    • 7.3.5. Orthopedic Diseases
    • 7.3.6. Infectious Diseases
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Therapeutic Area

8. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Rest of Europe
  • 8.3. Market Attractiveness Analysis, by Country/Sub-region

9. Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Service, 2017-2031
    • 9.2.1. Personal Promotion
      • 9.2.1.1. Promotional Sales Team
        • 9.2.1.1.1. Dedicated Sales Team
        • 9.2.1.1.2. Syndicated Sales Team
      • 9.2.1.2. Key Account Management
      • 9.2.1.3. Vacancy Management
    • 9.2.2. Non-personal Promotion
      • 9.2.2.1. Tele-detailing
      • 9.2.2.2. Interactive E-detailing
      • 9.2.2.3. Customer Service
      • 9.2.2.4. Medical Science Liaisons
      • 9.2.2.5. Patient Engagement Services
      • 9.2.2.6. Others
    • 9.2.3. Other Services
  • 9.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 9.3.1. Cardiovascular Disorders
    • 9.3.2. Oncology
    • 9.3.3. Metabolic Disorders
    • 9.3.4. Neurology
    • 9.3.5. Orthopedic Diseases
    • 9.3.6. Infectious Diseases
    • 9.3.7. Others
  • 9.4. Market Attractiveness Analysis
    • 9.4.1. By Service
    • 9.4.2. By Therapeutic Area

10. U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Service, 2017-2031
    • 10.2.1. Personal Promotion
      • 10.2.1.1. Promotional Sales Team
        • 10.2.1.1.1. Dedicated Sales Team
        • 10.2.1.1.2. Syndicated Sales Team
      • 10.2.1.2. Key Account Management
      • 10.2.1.3. Vacancy Management
    • 10.2.2. Non-personal Promotion
      • 10.2.2.1. Tele-detailing
      • 10.2.2.2. Interactive E-detailing
      • 10.2.2.3. Customer Service
      • 10.2.2.4. Medical Science Liaisons
      • 10.2.2.5. Patient Engagement Services
      • 10.2.2.6. Others
    • 10.2.3. Other Services
  • 10.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 10.3.1. Cardiovascular Disorders
    • 10.3.2. Oncology
    • 10.3.3. Metabolic Disorders
    • 10.3.4. Neurology
    • 10.3.5. Orthopedic Diseases
    • 10.3.6. Infectious Diseases
    • 10.3.7. Others
  • 10.4. Market Attractiveness Analysis
    • 10.4.1. By Service
    • 10.4.2. By Therapeutic Area

11. France Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Service, 2017-2031
    • 11.2.1. Personal Promotion
      • 11.2.1.1. Promotional Sales Team
        • 11.2.1.1.1. Dedicated Sales Team
        • 11.2.1.1.2. Syndicated Sales Team
      • 11.2.1.2. Key Account Management
      • 11.2.1.3. Vacancy Management
    • 11.2.2. Non-personal Promotion
      • 11.2.2.1. Tele-detailing
      • 11.2.2.2. Interactive E-detailing
      • 11.2.2.3. Customer Service
      • 11.2.2.4. Medical Science Liaisons
      • 11.2.2.5. Patient Engagement Services
      • 11.2.2.6. Others
    • 11.2.3. Other Services
  • 11.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 11.3.1. Cardiovascular Disorders
    • 11.3.2. Oncology
    • 11.3.3. Metabolic Disorders
    • 11.3.4. Neurology
    • 11.3.5. Orthopedic Diseases
    • 11.3.6. Infectious Diseases
    • 11.3.7. Others
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Service
    • 11.4.2. Therapeutic Area

12. Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Service, 2017-2031
    • 12.2.1. Personal Promotion
      • 12.2.1.1. Promotional Sales Team
        • 12.2.1.1.1. Dedicated Sales Team
        • 12.2.1.1.2. Syndicated Sales Team
      • 12.2.1.2. Key Account Management
      • 12.2.1.3. Vacancy Management
    • 12.2.2. Non-personal Promotion
      • 12.2.2.1. Tele-detailing
      • 12.2.2.2. Interactive E-detailing
      • 12.2.2.3. Customer Service
      • 12.2.2.4. Medical Science Liaisons
      • 12.2.2.5. Patient Engagement Services
      • 12.2.2.6. Others
    • 12.2.3. Other Services
  • 12.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 12.3.1. Cardiovascular Disorders
    • 12.3.2. Oncology
    • 12.3.3. Metabolic Disorders
    • 12.3.4. Neurology
    • 12.3.5. Orthopedic Diseases
    • 12.3.6. Infectious Diseases
    • 12.3.7. Others
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Service
    • 12.4.2. By Therapeutic Area

13. Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Service, 2017-2031
    • 13.2.1. Personal Promotion
      • 13.2.1.1. Promotional Sales Team
        • 13.2.1.1.1. Dedicated Sales Team
        • 13.2.1.1.2. Syndicated Sales Team
      • 13.2.1.2. Key Account Management
      • 13.2.1.3. Vacancy Management
    • 13.2.2. Non-personal Promotion
      • 13.2.2.1. Tele-detailing
      • 13.2.2.2. Interactive E-detailing
      • 13.2.2.3. Customer Service
      • 13.2.2.4. Medical Science Liaisons
      • 13.2.2.5. Patient Engagement Services
      • 13.2.2.6. Others
    • 13.2.3. Other Services
  • 13.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 13.3.1. Cardiovascular Disorders
    • 13.3.2. Oncology
    • 13.3.3. Metabolic Disorders
    • 13.3.4. Neurology
    • 13.3.5. Orthopedic Diseases
    • 13.3.6. Infectious Diseases
    • 13.3.7. Others
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Service
    • 13.4.2. By Therapeutic Area

14. Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Service, 2017-2031
    • 14.2.1. Personal Promotion
      • 14.2.1.1. Promotional Sales Team
        • 14.2.1.1.1. Dedicated Sales Team
        • 14.2.1.1.2. Syndicated Sales Team
      • 14.2.1.2. Key Account Management
      • 14.2.1.3. Vacancy Management
    • 14.2.2. Non-personal Promotion
      • 14.2.2.1. Tele-detailing
      • 14.2.2.2. Interactive E-detailing
      • 14.2.2.3. Customer Service
      • 14.2.2.4. Medical Science Liaisons
      • 14.2.2.5. Patient Engagement Services
      • 14.2.2.6. Others
    • 14.2.3. Other Services
  • 14.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 14.3.1. Cardiovascular Disorders
    • 14.3.2. Oncology
    • 14.3.3. Metabolic Disorders
    • 14.3.4. Neurology
    • 14.3.5. Orthopedic Diseases
    • 14.3.6. Infectious Diseases
    • 14.3.7. Others
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Service
    • 14.4.2. By Therapeutic Area

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis/Ranking, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Ashfield (UDG Healthcare plc)
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Company Financials
      • 15.3.1.3. Growth Strategies
      • 15.3.1.4. SWOT Analysis
    • 15.3.2. Syneos Health
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Company Financials
      • 15.3.2.3. Growth Strategies
      • 15.3.2.4. SWOT Analysis
    • 15.3.3. IQVIA, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Company Financials
      • 15.3.3.3. Growth Strategies
      • 15.3.3.4. SWOT Analysis
    • 15.3.4. GTS Solution
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Company Financials
      • 15.3.4.3. Growth Strategies
      • 15.3.4.4. SWOT Analysis
    • 15.3.5. EVERSANA
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Company Financials
      • 15.3.5.3. Growth Strategies
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. MaBiCo
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Company Financials
      • 15.3.6.3. Growth Strategies
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. Pharmaforce Ireland Ltd.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Company Financials
      • 15.3.7.3. Growth Strategies
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Sales Focus, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Company Financials
      • 15.3.8.3. Growth Strategies
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Amplity Health
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Company Financials
      • 15.3.9.3. Growth Strategies
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. PharmaLex GmbH
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Company Financials
      • 15.3.10.3. Growth Strategies
      • 15.3.10.4. SWOT Analysis
    • 15.3.11. Star OUTiCO
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Company Financials
      • 15.3.11.3. Growth Strategies
      • 15.3.11.4. SWOT Analysis
    • 15.3.12. NiSiPharm GmbH
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Company Financials
      • 15.3.12.3. Growth Strategies
      • 15.3.12.4. SWOT Analysis
Show more
Product Code: TMRGL84883

List of Tables

  • Table 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 07: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 08: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 09: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 10: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 11: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 12: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 13: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 14: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 15: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 16: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 17: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 18: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 19: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 20: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 21: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 22: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 23: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 24: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 25: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 26: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 27: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 28: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 29: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 30: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 31: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 32: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017-2031
  • Table 33: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017-2031
  • Table 34: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017-2031
  • Table 35: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017-2031
  • Table 36: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

List of Figures

  • Figure 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Service, 2021
  • Figure 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Therapeutic Area, 2021
  • Figure 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Country/Sub-region, 2021
  • Figure 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 07: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Personal Promotion, 2017-2031
  • Figure 08: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Non-personal Promotion, 2017-2031
  • Figure 09: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 10: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 11: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area 2022-2031
  • Figure 12: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017-2031
  • Figure 13: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Oncology, 2017-2031
  • Figure 14: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Metabolic Disorders, 2017-2031
  • Figure 15: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Neurology, 2017-2031
  • Figure 16: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Orthopedic Diseases, 2017-2031
  • Figure 17: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Infectious Diseases, 2017-2031
  • Figure 18: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 19: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 20: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 21: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 22: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 23: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 24: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 25: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 26: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 27: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 28: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 29: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 30: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 31: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 33: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 34: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 35: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 36: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 38: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 39: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 40: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 41: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 42: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 43: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 44: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 45: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 46: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 47: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
  • Figure 48: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022-2031
  • Figure 49: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
  • Figure 50: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!